12,372 trials
Fetal Alcohol Syndrome · Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Pittsburg Side-Effects Scale: Motor Tics — 0.15; 0.20; 0.31; 0.27 units on a scale
Pulmonary Arterial Hypertension
Primary: Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan — 7275.1; 8535.4 h*ng/mL
Bipolar I Disorder
Primary: Change in PANSS Excited Component (PEC) Score From Baseline Following Dose #1 of Staccato Loxapine, Compared With Placebo — -4.9; -8.1; -9.0 units on a scale — p=<0.0001
Patients With Schizophrenia and Acute Agitation
Primary: Change in PANSS-EC From Baseline — -5.5; -8.1; -8.6 units on a scale — p=0.0004
Renal Function · Endothelial Function · Blood Pressure
Primary: Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance [Vitamin D] — 35.7; 35.9 mL/min per 1.73 m^2 — p=0.72
Schizophrenia
Primary: Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Total Score — -7.9 units on a scale
Polycystic Ovary Syndrome · Disorder of Glucose Regulation
Primary: Glucose Metabolism — 3; 6; 10 Participants — p=.007
Rheumatoid Arthritis
Primary: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 — 62; 72; 49; 66.7 Percentage of participants — p=0.1155
Chemotherapy-induced Neutropenia · Breast Cancer
Primary: Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy — 1.36; 1.19; 1.34; 1.19 days — p=0.05
Osteoarthritis
Primary: Absolute Change in the Total WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Subscale Score for the Target Knee — 5.8; 5.9 units on a scale
Obesity · Diabetes · Hypertension
Primary: Change in Abdominal Fat Mass — -192.6; -21.9; -275 Cubic cm
Acne Vulgaris
Primary: Mean Percent Change in the Number of Inflamed Lesions (Papules/Pustules) — 72.3; 71.1; 39.1 percentage change from baseline
Hereditary Orotic Aciduria
Primary: Patients With Stable Predetermined Principal Hematologic Parameters — 4 Participants
Schizophrenia
Primary: Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Total Score — -19.6; -16.5; -21.6 units on a scale
Neuroblastoma
Primary: Overall Survival (OS) Rates — 99.4; 93.5; 88.4 percentage of participants